Biomm

Biomm ROE

The Return on Equity (ROE) of Biomm (BIOM3.SA) as of Nov 11, 2026 is -2.13 %. In the previous year, Return on Equity (ROE) was -29.39 % — a change of -92.74% (higher).

ROE

-2.13 %

YoY

-92.74%

Last updated:

In 2025, Biomm's return on equity (ROE) was -2.13 %, a -92.74% increase from the -29.39 % ROE in the previous year.

The Biomm ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-40.12 BRL
Jan 1, 2019
-36.35 BRL
Jan 1, 2020
-36.96 BRL
Jan 1, 2021
-71.93 BRL
Jan 1, 2022
-58.17 BRL
Jan 1, 2023
-66.00 BRL
Jan 1, 2024
-29.39 BRL
Jan 1, 2025
-2.13 BRL
The Biomm ROE history
YEARROEYoY
-2.13 %-92.74%
-29.39 %-55.47%
-66.00 %+13.45%
-58.17 %-19.12%
-71.93 %+94.62%
-36.96 %+1.68%
-36.35 %-9.40%
-40.12 %-37.60%
-64.30 %-7.06%
-69.18 %-1,061.64%
7.19 %-160.60%
-11.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

ROE Details

Decoding Biomm's Return on Equity (ROE)

Biomm's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Biomm's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Biomm's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Biomm’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Biomm stock

Return on Equity (ROE) of Biomm is -2.13 % in 2025.

Return on Equity (ROE) of Biomm changed from -29.39 % to -2.13 %, representing a -92.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Biomm since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biomm

All Key Metrics — Biomm